Medical costs associated with metastatic breast cancer in younger, midlife, and older women

American Cancer Society How Common is Breast Cancer? (2017). https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html. Accessed 30 July 2018

[2]

Johnson RH, Chien FL, Bleyer A (2013) Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA J Am Med Assoc. https://doi.org/10.1001/jama.2013.776 10.1001/jama.2013.776

[3]

Chollet-Hinton L, Anders CK, Tse CK et al (2016) Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina breast cancer study: a case-control study. Breast Cancer Res. https://doi.org/10.1186/s13058-016-0736-y 10.1186/s13058-016-0736-y

[4]

Anders CK, Johnson R, Litton J et al (2009) Breast cancer before age 40 years. Semin Oncol. https://doi.org/10.1053/j.seminoncol.2009.03.001 10.1053/j.seminoncol.2009.03.001

[5]

Lee HB, Han W (2014) Unique features of young age breast cancer and its management. J Breast Cancer. https://doi.org/10.4048/jbc.2014.17.4.301 10.4048/jbc.2014.17.4.301

[6]

Maggard MA, O’Connell JB, Lane KE et al (2003) Do young breast cancer patients have worse outcomes? J Surg Res. https://doi.org/10.1016/S0022-4804(03)00179-3 10.1016/s0022-4804(03)00179-3

[7]

Fredholm H, Eaker S, Frisell J et al (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE. https://doi.org/10.1371/journal.pone.0007695 10.1371/journal.pone.0007695

[8]

Howard-Anderson J, Ganz PA, Bower JE, Stanton AL (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 104:386 10.1093/jnci/djr541

[9]

Trivers KF, Fink AK, Partridge AH et al (2014) Estimates of young breast cancer survivors at risk for infertility in the US. Oncologist. https://doi.org/10.1634/theoncologist.2014-0016 10.1634/theoncologist.2014-0016

[10]

Allaire BT, Ekwueme DU, Guy GP et al (2016) Medical care costs of breast cancer in privately insured women aged 18–44 years. Am J Prev Med. https://doi.org/10.1016/j.amepre.2015.08.035 10.1016/j.amepre.2015.08.035

[11]

Ekwueme DU, Allaire BT, Guy GP et al (2016) Treatment Costs of breast cancer among younger women aged 19–44 years enrolled in medicaid. Am J Prev Med. https://doi.org/10.1016/j.amepre.2015.10.017 10.1016/j.amepre.2015.10.017

[12]

Allaire BT, Ekwueme DU, Poehler D et al (2017) Breast cancer treatment costs in younger, privately insured women. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-017-4249-x 10.1007/s10549-017-4249-x

[13]

Trogdon JG, Ekwueme DU, Poehler D et al (2017) Medical costs of treating breast cancer among younger Medicaid beneficiaries by stage at diagnosis. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-017-4386-2 10.1007/s10549-017-4386-2

[14]

Surveillance Research Program NCI (2019) SEER*Explorer: an interactive website for SEER cancer statistics. https://seer.cancer.gov/explorer/. Accessed 30 Sept 2019

[15]

Extending Survival with Chemotherapy in Metastatic Breast Cancer

Joyce O'Shaughnessy

The Oncologist 2005 10.1634/theoncologist.10-90003-20

[16]

Campbell JD, Ramsey SD (2009) The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics 273:199 10.2165/00019053-200927030-00003

[17]

Mariotto AB, Robin Yabroff K, Shao Y et al (2011) Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djq495 10.1093/jnci/djq495

[18]

Meyer AM, Olshan AF, Green L et al (2014) Big data for population-based cancer research: the integrated cancer information and surveillance system. N C Med J. https://doi.org/10.18043/ncm.75.4.265 10.18043/ncm.75.4.265

[19]

Short PF, Graefe DR, Schoen C (2003) Churn, churn, churn: how instability of health insurance shapes America’s uninsured problem. Issue Brief (Commonw Fund)

[20]

Primary Care Case Management in North Carolina. https://www.cga.ct.gov/2008/rpt/2008-R-0622.htm. Accessed 30 July 2018

[21]

Chubak J, Yu O, Pocobelli G et al (2012) Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djs233 10.1093/jnci/djs233

[22]

Iacus SM, King G, Porro G (2012) Causal inference without balance checking: coarsened exact matching. Polit Anal. https://doi.org/10.1093/pan/mpr013 10.1093/pan/mpr013

[23]

Civic Impulse L (2009) H.R. 1740 (111th): Breast Cancer Education and Awareness Requires Learning Young Act of 2009

[24]

Iacus SM, King G, Porro G (2009) Software for coarsened exact matching. J Stat Softw. https://doi.org/10.18637/jss.v030.i09 10.18637/jss.v030.i09

[25]

Centers for Medicare & Medicaid Services (2019) Medicare Provider Utilization and Payment Data. https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/medicare-provider-charge-data. Accessed 30 Sept 2019

[26]

Dalton K, Freeman S, Bragg A (2008) Refining cost to charge ratios for calculating APC and MS-DRG relative payment weights final report. RTI International, Research Triangle Park

[27]

Smith MW, Friedman B, Karaca Z, Wong HS (2015) Predicting inpatient hospital payments in the United States: a retrospective analysis. BMC Health Serv Res. https://doi.org/10.1186/s12913-015-1040-8 10.1186/s12913-015-1040-8

[28]

Buntin MB, Zaslavsky AM (2004) Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ. https://doi.org/10.1016/j.jhealeco.2003.10.005 10.1016/j.jhealeco.2003.10.005

[29]

Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol. https://doi.org/10.1016/S0895-4356(00)00256-0 10.1016/s0895-4356(00)00256-0

[30]

FRED Graph Observations (2019) In: Federal Reserve Economic Data. https://fred.stlouisfed.org/series/CPIMEDSL. Accessed 30 Sept 2019

[31]

Blumen H, Fitch K, Polkus V (2016) Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Heal Drug Benefits 9:23

[32]

Edwards BK, Noone AM, Mariotto AB et al (2014) Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120:1290 10.1002/cncr.28509

[33]

Dusetzina SB (2016) Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000–2014. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2016.0648 10.1001/jamaoncol.2016.0648

[34]

Centers for Disease Control and Prevention (2019) DP19–1906: multiple approaches to support young breast cancer survivors and metastatic breast cancer patients. https://www.cdc.gov/cancer/ncccp/dp19-1906.htm. Accessed 20 Dec 2019

[35]

Franc BL, Copeland TP, Thombley R et al (2018) Geographic variation in postoperative imaging for low-risk breast cancer. JNCCN J Natl Compr Cancer Netw. https://doi.org/10.6004/jnccn.2018.7024 10.6004/jnccn.2018.7024

[36]

Financial Toxicity in Advanced and Metastatic Cancer: Overburdened and Underprepared

Jason Rotter, Jennifer C. Spencer, Stephanie B. Wheeler

Journal of Oncology Practice 2019 10.1200/jop.18.00518

Metrics

29

Citations

36

References

Details

Published: Apr 28, 2020
Vol/Issue: 181(3)
Pages: 653-665
License: View

Authors

J

Justin G. Trogdon

C

Christopher D. Baggett

A

Anagha Gogate

K

Katherine E. Reeder-Hayes

2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; 3Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

J

Jason Rotter

University of North Carolina at Chapel Hill, Chapel Hill, NC

Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia

Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; Department of Health Policy and Management, University of North Carolina at Chapel Hill

Funding

Centers for Disease Control and Prevention Award: SIP 17-004

Cite This Article

Justin G. Trogdon, Christopher D. Baggett, Anagha Gogate, et al. (2020). Medical costs associated with metastatic breast cancer in younger, midlife, and older women. Breast Cancer Research and Treatment, 181(3), 653-665. https://doi.org/10.1007/s10549-020-05654-x

Medical costs associated with metastatic breast cancer in younger, midlife, and older women

You May Also Like